CompoAtlas

SG Brand Yi Yin Capsule

SG Brand Yi Yin Capsule : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
Polygonum multiflorumPolygonum multiflorum[78.4 mg,450 mg]Not identified
Rehmannia glutinosaRehmannia glutinosa[64.3 mg,450 mg]Not identified
Polygonatum sibiricumPolygonatum sibiricum[45.0 mg,450 mg]Not identified
Astragalus membranaceusAstragalus membranaceus[45.0 mg,450 mg]Not identified
Morus albaMorus alba[45.0 mg,450 mg]Not identified
Litchi chinensisLitchi chinensis[45.0 mg,450 mg]Not identified
Pueraria lobataPueraria lobata[36.0 mg,450 mg]Not identified
Ostrea gigasOstrea gigas[32.1 mg,450 mg]Not identified
Cuscuta chinensisCuscuta chinensis[16.7 mg,450 mg]Not identified
Paeonia suffruticosaPaeonia suffruticosa[12.9 mg,450 mg]Not identified
Panax quinquefoliusPanax quinquefolius[12.9 mg,450 mg]Not identified
Ligusticum chuanxiongLigusticum chuanxiong[10.3 mg,450 mg]Not identified
Atractylodes lanceaAtractylodes lancea[6.4 mg,450 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
MAL23036102T
Type
Natural product
Published status
PRODUCT APPROVED
Licence holder
SG GLOBAL BIOTECH SDN. BHD.
Manufacturer
SG GLOBAL BIOTECH SDN. BHD.
Registration period starting
2023-03-21
Published validity end
2028-03-21

Original register data

View published fields and their variants
Active ingredients
Polygonum multiflorum[78.4 mg,450 mg],Rehmannia glutinosa[64.3 mg,450 mg],Polygonatum sibiricum[45.0 mg,450 mg],Astragalus membranaceus[45.0 mg,450 mg],Morus alba[45.0 mg,450 mg],Litchi chinensis[45.0 mg,450 mg],Pueraria lobata[36.0 mg,450 mg],Ostrea gigas[32.1 mg,450 mg],Cuscuta chinensis[16.7 mg,450 mg],Paeonia suffruticosa[12.9 mg,450 mg],Panax quinquefolius[12.9 mg,450 mg],Ligusticum chuanxiong[10.3 mg,450 mg],Atractylodes lancea[6.4 mg,450 mg]
Valid until
2028-03-21
Registration date
2023-03-21
Published description
NATURAL PRODUCT
Licence holder
SG GLOBAL BIOTECH SDN. BHD.
Producer
SG GLOBAL BIOTECH SDN. BHD.
Published name
SG Brand Yi Yin Capsule
Published reference
202211159513T
Registration number
MAL23036102T
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL23036102T

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Astragalus membranaceus
    Read the warning, when it applies and the studies cited

    ASTRAGALUS - ASTRAGALUS MEMBRANACEUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an autoimmune disorder (Brinker 2010; Upton 1999).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Astragalus Root. Santa Cruz (CA): American Herbal Pharmacopoeia; 1999.

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use if you have exterior excess, stagnation, yin deficiency or excess heat (Bensky et al. 2004; Chen and Chen 2004).

    Sources cited by Health Canada (2)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Health Canada monograph dated 30 May 2025

  • Panax quinquefolius
    Read the warning, when it applies and the studies cited

    PANAX QUINQUEFOLIUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or digoxin (Brinker 2010; Dasgupta et al. 2007; Elmer et al. 2007; Yuan et al. 2004).

    Sources cited by Health Canada (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dasgupta A, Kang E, Olsen M, Actor JK, Datta P. Interference of Asian, American, and Indian (Ashwagandha) ginseng in serum digoxin measurements by a fluorescence polarization immunoassay can be minimized by using a new enzyme-linked chemiluminescent immunosorbent or turbidimetric assay. Archives of Pathology & Laboratory Medicine 2007;131(4):619-621. PubMed
    • Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. The Annals of Pharmacotherapy 2007;41(10):1617-1624. PubMed
    • Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. American ginseng reduces warfarin's effect in healthy patients. Annals of internal medicine 2004;141(1):23-27. PubMed Randomised trial

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Dascalu et al. 2007; Vuksan et al. 2000a,b,c).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dascalu A, Sievenpiper JL, Jenkins AL, Stavro MP, Leiter LA, Arnason JT, Vuksan V. Five batches representative of Ontario-grown American ginseng root produce comparable reductions of postprandial glycemia in healthy individuals. Canadian Journal of Physiology and Pharmacology 2007;85(9):856-864. PubMed
    • Vuksan V, Xu Z, Jenkins AL, Belgan U, Sievenpiper JL, Leiter LA, Josse RG, Stavro MP.American ginseng (Panax quinquefolium L.) improves long-term glycemic control in type 2 diabetes: double-blind placebo controlled crossover trial. Diabetes 2000a;49 (Suppl.1):A95.

    Condition of application: All products except Glucose levels and Adaptogen - immune system.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “SG Brand Yi Yin Capsule”, https://compoatlas.com/en/supplements/malaysia/MAL23036102T-sg-brand-yi-yin-capsule, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line